Urinary Tract Infections Caused by Extended-spectrum Beta-lactamase-producing Enterobacteria

Launched by UNIVERSITY HOSPITAL, STRASBOURG, FRANCE · Mar 28, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how general practitioners manage urinary tract infections (UTIs) caused by a specific type of bacteria known as Extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E). These bacteria are resistant to many common antibiotics, making UTIs harder to treat. The goal of the study is to find better ways for doctors to handle these infections and improve patient care.

To be eligible for this trial, participants must be adults aged 18 or older who have been treated for an Enterobacteriaceae UTI in a primary care setting between June 1, 2024, and December 31, 2024. Participants will need to agree to allow their data to be used for research purposes, and their primary care physician must also consent to take part in the study. If you join the trial, you can expect to help researchers understand more about these challenging infections and potentially contribute to better treatment options for future patients. If you have any questions or concerns, your doctor will be there to guide you through the process.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult (≥18 years old)
• • Subject with an Enterobacteriaceae urinary tract infection treated in a primary care setting for urinary tract infection between June 1, 2024 and December 31, 2024
• • Subject not objecting, after being informed, to the reuse of their data for the purposes of this research.
• • The subject's primary care physician agreeing to participate in the study
• Exclusion Criteria:
• • Subject and/or their primary care physician having expressed their opposition to participating in the study
• • Subject under legal protection
• • Subject under guardianship or curatorship